IMARC Group, a leading market research company, has recently released a report titled "Hospital Infection Therapeutics Market Report by Drug Type (Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs, and Others), Indication (Blood Stream Infections, Urinary Tract Infections, Surgical Site Infections, Pneumonia, and Others), and Region 2024-2032". The study provides a detailed analysis of the industry, including the hospital infection therapeutics market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global hospital infection therapeutics market size reached US$ 12.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.55% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/hospital-infection-therapeutics-market/requestsample
Factors Affecting the Growth of the Hospital Infection Therapeutics Industry:
- Increasing Prevalence of Hospital-Acquired Infections (HAIs): The global hospital infection therapeutics market is primarily driven by the rising prevalence of hospital-acquired infections (HAIs), which include pneumonia, bloodstream infections, surgical site infections, and urinary tract infections among others. HAIs are infections patients acquire while receiving treatment for other conditions within a healthcare setting, significantly impacting morbidity, mortality, and healthcare costs worldwide. The surge in HAIs is attributed to several factors, including the increased use of invasive procedures and devices, prolonged hospital stays, and the high susceptibility of the immunocompromised patient population. The necessity to manage and treat these infections effectively has led to heightened demand for hospital infection therapeutics, propelling market growth.
- Advancements in Antimicrobial Resistance: The challenge of antimicrobial resistance (AMR) has become a pivotal driver for innovation and growth in the hospital infection therapeutics market. AMR occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. The escalating prevalence of drug-resistant pathogens necessitates the development of new and effective antimicrobial agents. Pharmaceutical companies and research institutions are increasingly investing in R&D activities to discover novel therapeutics capable of combating resistant strains, thus fueling market expansion.
- Government Initiatives and Funding: Government initiatives and increased funding for healthcare infrastructure and research activities significantly contribute to the growth of the hospital infection therapeutics market. Governments worldwide are implementing stringent guidelines and recommendations for infection prevention and control (IPC) within healthcare facilities to reduce the incidence of HAIs. Additionally, public and private funding for research on new treatment modalities and infection control practices is expanding. These financial investments facilitate the development of innovative therapeutics and diagnostic technologies, enabling better management of hospital infections.
Hospital Infection Therapeutics Market Report Segmentation:
Breakup by Drug Type:
- Anti-bacterial Drugs
- Anti-fungal Drugs
- Anti-viral Drugs
- Others
Anti-bacterial drugs account for the majority of the market share due to the high prevalence of bacterial infections in hospitals, which necessitates extensive use of antibiotics to prevent and treat these infections effectively.
Breakup by Indication:
- Blood Stream Infections
- Urinary Tract Infections
- Surgical Site Infections
- Pneumonia
- Others
Surgical site infections hold the largest share of the industry as they are one of the most common hospital-acquired infections, arising from surgeries and procedures, thus requiring significant therapeutic intervention to manage and treat.
Breakup by Region:
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Europe leads the market, accounting for the largest hospital infection therapeutics market share, due to its stringent healthcare regulations, well-established healthcare infrastructure, and high awareness and adoption of infection control practices.
Global Hospital Infection Therapeutics Market Trends:
The global hospital infection therapeutics market is witnessing the growing focus on personalized medicine and the development of targeted therapy approaches. This trend is propelled by advancements in genomics and microbiology, enabling the creation of treatments tailored to the specific pathogens and resistance patterns found in individual patients. Additionally, the integration of artificial intelligence and machine learning technologies in drug discovery and development processes is streamlining the identification of novel therapeutic candidates and accelerating their time-to-market. Another noteworthy development is the increasing collaboration between pharmaceutical companies and biotechnology firms, fostering innovation and the exploration of untapped therapeutic areas. Moreover, the expansion of telemedicine and remote patient monitoring systems in response to the COVID-19 pandemic has highlighted the importance of developing and implementing effective infection control strategies beyond traditional hospital settings.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=2393&flag=C
Top Companies Operated in Hospital Infection Therapeutics Industry:
- Allergan Plc (AbbVie Inc.)
- AstraZeneca Plc
- Bayer Aktiengesellschaft
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc.
- Sanofi S.A.
Key Highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments